Keywords
Lithium
Nephritis, Interstitial
Carbamazepine
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To report the case of a patient diagnosed with acute interstitial nephritis, secondary to the use of lithium in the treatment of Bipolar Disorder (TB), scientifically reviewing the correlation between the drug and nephropathies. Case detail: Female patient, 24 years old, attended in private practice reporting suicidal ideas, with a diagnosis of severe dysphoric syndrome. Sessions of cognitive-behavioral psychotherapy were initiated, as well as its drug treatment, followed by several crises and unsuccessful attempts to introduce lithium as a viable option. However, after a decade of treatment, the patient agreed to start its use. Eight years later, acute interstitial nephritis was diagnosed, secondary to the use of lithium, replacing it with carbamazepine. The patient continued her treatment for another four years, until she was referred to another professional in a different location. Final considerations: TB is a complex psychiatric disorder, with drastic mood and behavioral changes, with lithium being its first-line treatment. However, this medication is responsible for developing progressive kidney disease in a significant percentage of patients, and some of them develop severe conditions, such as interstitial nephritis.
References
ABREU LN, et al. Suicidal ideation and suicide attempts in bipolar disorder type I: an update for the clinician, 2009; 31(3): 271-280.
ARIAS F, et al. Bipolar disorder and substance use disorders. Madrid study on the prevalence of dual disorders/pathology. Adicciones, 2017; 29(3): 186-194.
AUGUSTA DOS REIS J, et al. Lítio: tratamento de primeira escolha no transtorno bipolar. Revista Científica da Faculdade de Educação e Meio Ambiente, 2015; 6(1): 27-37.
BOSAIPO NB, et al. Transtorno bipolar: uma revisão dos aspectos conceituais e clínicos. Medicina, 2017; 50(1): 72-84.
CUNHA LCDA, et al. Carbamazepine and carbamazepine-10, 11-epoxide therapeutic drug monitoring and biochemical and hematological evaluation in bipolar disorder outpatients. Research, Society and Development, 2021; 10(11): 1-15.
FIGUEIREDO AL, et al. O uso da psicoeducação no tratamento do transtorno bipolar, 2009: 11 (1): 12-24.
MELLO DR, et al. Impactos metabólicos na nefrotoxicidade por lítio. Revista de extensão e iniciação científica da UniSociesc, 2021; 8(2): 1-15.
MAGGIO I, et al. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncology, 2021; 10(2): 1-16.
MIKLOWITZ DJ, JOHNSON SL. The Psychopathology and Treatment of Bipolar Disorder. Annual Review of Clinical Psychology, 2006; 2(1):199–235.
MIRANDA-SCIPPA A. Transtorno bipolar e suicídio, 2020; 36 (1) S6-S8.
MISSIO G. et al. Um estudo controlado randomizado comparando lítio mais ácido valproico versus lítio mais carbamazepina em pacientes jovens com transtorno bipolar tipo 1: o estudo LICAVAL. Trials for BMC Medicine, 2009; 20(608): 1-9.
MORENO RA, et al. Diagnóstico, tratamento e prevenção da mania e da hipomania no transtorno bipolar. Rev. Psiq. Clín., 2005; 32 (1): 39-48.
RAY-GRIFFITH SL, et al. Pregnancy and Electroconvulsive Therapy: A Multidisciplinary Approach. The Journal of ECT, 2016; 32(2): 104–112.
STAHL SM. Lítio. In: Fundamentos de Psicofarmacologia de Sthal. 6 ed. São Paulo: Artmed LTDA, 2019; 409-414p.
ZANATELLI MM, et al. Meningioma gigante como causa de alterações psiquiátricas. Arq Bras Neurocir, 2009; 28(4): 170-173.